El perfil de seguridad de las estatinas

HMG-CoA reductase inhibitors (statins) are the treatment of choice for patients with hypercholesterolaemia. Several large-scale clinical trials have examined the efficacy and tolerability of statins, providing a wealth of information on their safety and adverse effect profile. Adverse hepatic effect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Prieto D,Juan Carlos
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2001
Materias:	Adverse drug reaction reporting systems Cerivastatin Hidroxymethylglutaryl-CoA reductase inhibitors Rhabdomyolysis Statins
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001001100001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872001001100001
record_format	dspace
spelling	oai:scielo:S0034-988720010011000012002-06-12El perfil de seguridad de las estatinasPrieto D,Juan Carlos Adverse drug reaction reporting systems Cerivastatin Hidroxymethylglutaryl-CoA reductase inhibitors Rhabdomyolysis Statins HMG-CoA reductase inhibitors (statins) are the treatment of choice for patients with hypercholesterolaemia. Several large-scale clinical trials have examined the efficacy and tolerability of statins, providing a wealth of information on their safety and adverse effect profile. Adverse hepatic effect is reflected as asymptomatic elevations in serum levels of aminotransaminases. Myopathy, occasionally leading to myoglobulinuria secondary to rhabdomyolysis, is a rare and potentially fatal complication. Cerivastatin, the last statin approved for use in humans, was voluntarily withdrawn from the market by Bayer, because fatal rhabdomyolysis was most frequently reported with cerivastatin than for other approved statins. The concomitant use of statins with drugs that inhibit CYP3A4 (cyclosporin, erythromycin, clarithromycin, itraconazole, and ketoconazole), may result in increased plasma concentrations of HMG-CoA reductase inhibitors leading occasionally to myotoxicity. Fibric acid derivatives can produce myotoxicity, and the association of both types of drugs increases the risk of this adverse event. The reason for the greater association of rhabdomyolysis with cerivastatin than with other statins is unknown. The efficiency of post marketing drug surveillance programs in different countries, was the clue for the awareness of this problem (Rev Méd Chile 2001; 129: 1237-40).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.129 n.11 20012001-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001001100001es10.4067/S0034-98872001001100001
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Adverse drug reaction reporting systems Cerivastatin Hidroxymethylglutaryl-CoA reductase inhibitors Rhabdomyolysis Statins
spellingShingle	Adverse drug reaction reporting systems Cerivastatin Hidroxymethylglutaryl-CoA reductase inhibitors Rhabdomyolysis Statins Prieto D,Juan Carlos El perfil de seguridad de las estatinas
description	HMG-CoA reductase inhibitors (statins) are the treatment of choice for patients with hypercholesterolaemia. Several large-scale clinical trials have examined the efficacy and tolerability of statins, providing a wealth of information on their safety and adverse effect profile. Adverse hepatic effect is reflected as asymptomatic elevations in serum levels of aminotransaminases. Myopathy, occasionally leading to myoglobulinuria secondary to rhabdomyolysis, is a rare and potentially fatal complication. Cerivastatin, the last statin approved for use in humans, was voluntarily withdrawn from the market by Bayer, because fatal rhabdomyolysis was most frequently reported with cerivastatin than for other approved statins. The concomitant use of statins with drugs that inhibit CYP3A4 (cyclosporin, erythromycin, clarithromycin, itraconazole, and ketoconazole), may result in increased plasma concentrations of HMG-CoA reductase inhibitors leading occasionally to myotoxicity. Fibric acid derivatives can produce myotoxicity, and the association of both types of drugs increases the risk of this adverse event. The reason for the greater association of rhabdomyolysis with cerivastatin than with other statins is unknown. The efficiency of post marketing drug surveillance programs in different countries, was the clue for the awareness of this problem (Rev Méd Chile 2001; 129: 1237-40).
author	Prieto D,Juan Carlos
author_facet	Prieto D,Juan Carlos
author_sort	Prieto D,Juan Carlos
title	El perfil de seguridad de las estatinas
title_short	El perfil de seguridad de las estatinas
title_full	El perfil de seguridad de las estatinas
title_fullStr	El perfil de seguridad de las estatinas
title_full_unstemmed	El perfil de seguridad de las estatinas
title_sort	el perfil de seguridad de las estatinas
publisher	Sociedad Médica de Santiago
publishDate	2001
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872001001100001
work_keys_str_mv	AT prietodjuancarlos elperfildeseguridaddelasestatinas
_version_	1718435999201099776

El perfil de seguridad de las estatinas

Ejemplares similares